266 related articles for article (PubMed ID: 23212150)
1. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
Pfeifer H; Wassmann B; Bethge W; Dengler J; Bornhäuser M; Stadler M; Beelen D; Vucinic V; Burmeister T; Stelljes M; Faul C; Dreger P; Kiani A; Schäfer-Eckart K; Schwerdtfeger R; Lange E; Kubuschok B; Horst HA; Gramatzki M; Brück P; Serve H; Hoelzer D; Gökbuget N; Ottmann OG;
Leukemia; 2013 Jun; 27(6):1254-62. PubMed ID: 23212150
[TBL] [Abstract][Full Text] [Related]
2. Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Nishiwaki S; Miyamura K; Kato C; Terakura S; Ohashi K; Sakamaki H; Nakao S; Harigae H; Kodera Y
Anticancer Res; 2010 Jun; 30(6):2415-8. PubMed ID: 20651401
[TBL] [Abstract][Full Text] [Related]
3. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
4. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim DW; Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Kim HJ; Min CK; Lee JW; Min WS; Park CW
Leukemia; 2012 Nov; 26(11):2367-74. PubMed ID: 22705993
[TBL] [Abstract][Full Text] [Related]
5. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
[TBL] [Abstract][Full Text] [Related]
7. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
[TBL] [Abstract][Full Text] [Related]
8. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B; Pfeifer H; Stadler M; Bornhaüser M; Bug G; Scheuring UJ; Brück P; Stelljes M; Schwerdtfeger R; Basara N; Perz J; Bunjes D; Ledderose G; Mahlberg R; Binckebanck A; Gschaidmeier H; Hoelzer D; Ottmann OG
Blood; 2005 Jul; 106(2):458-63. PubMed ID: 15817679
[TBL] [Abstract][Full Text] [Related]
9. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Shi HX; Han W; Zhan XH; Wang Y; Zhao T; Huang XJ
Chin Med J (Engl); 2011 Jan; 124(2):246-52. PubMed ID: 21362375
[TBL] [Abstract][Full Text] [Related]
10. The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zhang FH; Ling YW; Zhai X; Zhang Y; Huang F; Fan ZP; Zhou HS; Jiang QL; Sun J; Liu QF
Hematology; 2013 May; 18(3):151-7. PubMed ID: 23394269
[TBL] [Abstract][Full Text] [Related]
11. [Efficacies of hematopoietic stem cell transplantation plus imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparative study].
Chen J; Wu DP; Chen F; Zhao Y; Sun AN; Qiu HY
Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(8):583-7. PubMed ID: 23663336
[TBL] [Abstract][Full Text] [Related]
12. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
[TBL] [Abstract][Full Text] [Related]
13. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
Bassan R; Rossi G; Pogliani EM; Di Bona E; Angelucci E; Cavattoni I; Lambertenghi-Deliliers G; Mannelli F; Levis A; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Borghero C; Romani C; Spinelli O; Tosi M; Oldani E; Intermesoli T; Rambaldi A
J Clin Oncol; 2010 Aug; 28(22):3644-52. PubMed ID: 20606084
[TBL] [Abstract][Full Text] [Related]
15. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival.
Burke MJ; Trotz B; Luo X; Baker KS; Weisdorf DJ; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Jan; 43(2):107-13. PubMed ID: 18776928
[TBL] [Abstract][Full Text] [Related]
16. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.
Riva G; Luppi M; Lagreca I; Barozzi P; Quadrelli C; Vallerini D; Zanetti E; Basso S; Forghieri F; Morselli M; Maccaferri M; Paolini A; Fantuzzi V; Messerotti A; Maffei R; Iacobucci I; Martinelli G; Marasca R; Narni F; Comoli P; Potenza L
Br J Haematol; 2014 Jan; 164(2):299-302. PubMed ID: 24134676
[No Abstract] [Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Wassmann B; Scheuring U; Pfeifer H; Binckebanck A; Käbisch A; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2003 Oct; 17(10):1919-24. PubMed ID: 14513038
[TBL] [Abstract][Full Text] [Related]
19. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XY; Han W; Zhang XH; Wang Y; Zhang YY; Qin YZ; Liu YR; Huang XJ
J Hematol Oncol; 2012 Jun; 5():29. PubMed ID: 22682059
[TBL] [Abstract][Full Text] [Related]
20. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
